Search & Analyze

Symbiotec Pharmalab Ltd.

1,508.00+237.10 (+18.66%)

BSE · 06 Nov, 12:37 PM

: ₹8,166.31 Cr
: 74.30
: 3,52,364
: ₹1,525.00 - ₹1,320.40
: ₹1,310.00 - ₹933.80

Symbiotec Pharmalab Ltd. (SYMBIOTEC) share price is trading at ₹1,508.00 on the BSE as of November 6, 2026 at 12:37 PM, up by 18.66% from its of ₹1,270.90. In today's trading session SYMBIOTEC reached a of 1,525.00 and of 1,320.40. The for today is 1,451.44. Looking at , the stock is in Uptrend.

Stock Overview

₹1,325.00

₹1,270.90

₹1,451.44

Key Fundamentals

: 8,166.31 Cr₹8.17 Thousand Crore
: 17.10
: 74.30
: 5.45
: 233.38
: 241.78 Cr₹241.78 Crore
: 0.00 %
Sector
Industry: Pharmaceuticals & Drugs
: 11.22
: 0.34

Industry Comparison

Ratio	Company	Sector
	74.30	46.01
	0.34	0.20
	5.45	4.89
	0.92	1.81
	0.00 %	0.11 %
Operating Margin	27.16 %	19.14 %

Sector figures are the median of 156 listed Healthcare companies.

Peer Comparison

Name
SUN PHARMA. SUNPHARMA	1,861.65	39.94	4,46,672.19	0.88	1,995.07	-36.16%	16,198.71	11.88%	19.11
DIVI'S LAB. DIVISLAB	10,142.95	92.12	2,69,263.45	0.30	902.00	65.50%	3,080.00	27.80%	21.51
TORRENT PHAR TORNTPHARM	4,726.95	84.49	1,79,797.98	0.81	534.00	-9.64%	4,979.00	50.79%	19.27
LAURUSLABS LAURUSLABS	2,315.40	94.56	1,25,103.89	0.09	436.19	124.27%	2,206.37	33.44%	18.20
ZYDUSLIFE ZYDUSLIFE	1,200.00	28.55	1,19,700.46	0.08	927.70	-25.24%	7,909.60	29.17%	21.39
DR.REDDY'S DRREDDY	1,367.00	40.60	1,14,181.62	0.59	913.20	-31.69%	8,697.80	-1.48%	13.75
CIPLA LTD. CIPLA	1,401.35	39.09	1,13,213.39	0.93	851.51	-37.08%	7,403.93	-2.44%	16.00
Symbiotec Pharmalab Ltd. SYMBIOTEC	1,508.00	74.30	8,166.31	0.00	14.06	-53.00%	218.15	7.37%	12.41

Quarterly Results

consolidated figures in ₹ Crores · Quarterly

Particulars	Jun 2025	Jun 2026
	203.17	218.15
Expenses	145.21	172.95
	57.97	45.20
	28.53%	20.72%
	2.64	0.34
Interest	5.28	6.18
	10.51	21.82
	44.82	17.53
	33.25%	19.80%
	29.92	14.06
	5.47	2.24

Profit & Loss

consolidated figures in ₹ Crores · Annual

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
INCOME :
	681.80	575.08	723.32	760.58	878.63
	681.80	566.51	716.25	751.55	869.15
EXPENDITURE :
Increase/Decrease in Stock	-1.77	-16.58	8.38	11.91	13.38
Raw Material Consumed	353.96	308.42	312.63	285.49	302.09
Power & Fuel Cost	27.56	28.75	31.17	29.63	41.75
Employee Cost	83.64	94.08	104.08	122.28	154.34
Other Manufacturing Expenses	41.53	36.15	40.33	48.78	57.31
General and Administration Expenses	20.41	22.62	24.54	24.37	29.72
Selling and Distribution Expenses	5.98	12.93	10.88	15.23	16.10
Miscellaneous Expenses	19.06	10.61	12.19	11.15	15.80
	550.36	496.97	544.20	548.84	630.48
Operating Profit (Excl OI)	131.44	69.54	172.05	202.72	238.67
	3.00	6.46	7.09	4.43	3.11
	134.44	76.00	179.14	207.14	241.78
Interest	3.14	8.14	7.96	16.91	26.14
PBDT	131.29	67.87	171.17	190.23	215.64
	25.83	28.52	38.82	43.10	53.28
Profit Before Taxation & Exceptional Items	105.47	39.34	132.35	147.13	162.36
Exceptional Income / Expenses					-8.99
	105.47	38.27	130.98	146.98	153.36
Provision for Tax	28.18	14.78	30.93	50.19	43.46
	77.29	23.49	100.06	96.79	109.90
Extra items	0.00	0.00	0.00	0.00	0.00
Share of Associate	0.24
Consolidated Net Profit	77.53	23.49	100.06	96.79	109.90
Profit Balance B/F	348.46	425.25	449.01	548.40	644.60
Appropriations	425.99	448.74	549.07	645.19	754.51
	70.89	21.48	91.49	88.50	17.52
Adjusted EPS	14.18	4.30	18.30	17.70	17.52

Balance Sheet

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
	10.94	10.94	10.94	10.94	12.55
Share Warrants & Outstandings				4.29	0.69
Total Reserves	587.77	610.60	704.11	799.67	1,136.49
Reserve excluding Revaluation Reserve	587.77	610.60	704.11	799.67	1,136.49
Revaluation reserve	0.00	0.00	0.00	0.00	0.00
	598.70	621.53	715.05	814.89	1,149.73
Minority Interest	-0.11	-0.09	-0.21	-0.19	-0.14
Secured Loans	0.73	112.00	195.24	253.01	68.41
Deferred Tax Assets / Liabilities	20.45	20.16	19.94	21.99	5.81
Other Long Term Liabilities	1.13	2.08	2.84	4.09	7.84
Long Term Provisions	5.58	6.24	10.70	13.25	21.57
Total Non-Current Liabilities	27.89	140.48	228.73	292.35	103.64
Trade Payables	88.77	86.61	227.61	88.50	138.33
Other Current Liabilities	29.34	30.36	66.61	140.56	87.21
Short Term Borrowings	63.92	105.28	50.30	228.41	287.50
Short Term Provisions	6.66	5.83	6.69	15.13	14.53
Total Current Liabilities	188.70	228.07	351.21	472.60	527.57
Total Liabilities	815.18	989.99	1,294.79	1,579.65	1,780.79
Gross Block	406.92	454.15	604.58	630.16	1,363.75
Less: Accumulated Depreciation	126.92	154.87	193.15	228.63	279.37
	280.00	299.28	411.43	401.54	1,084.39
	39.68	182.13	208.32	568.17	64.48
Non Current Investments	5.41	4.82	3.51	1.45	4.48
Long Term Investment	5.41	4.82	3.51	1.45	4.48
Long Term Loans & Advances	62.12	103.58	124.43	77.83	103.92
Other Non Current Assets	2.51	0.01	1.89	1.35	2.04
Total Non-Current Assets	389.71	589.82	786.58	1,086.79	1,295.25
Inventories	245.66	243.77	335.79	261.45	236.88
Sundry Debtors	143.51	111.95	125.67	175.65	197.60
Cash and Bank	10.69	5.71	7.56	26.47	10.13
Other Current Assets	12.15	19.85	19.74	21.49	30.55
Short Term Loans and Advances	13.46	18.89	19.45	7.79	10.39
Total Current Assets	425.46	400.17	508.21	492.86	485.54
Net Current Assets (Including Current Investments)	236.77	172.10	157.00	20.26	-42.02
Total Assets	815.18	989.99	1,294.79	1,579.65	1,780.79
	1.13		1.15
Total Debt	64.66	217.88	247.21	540.92	387.91
	547.46	568.34	653.85	741.22	183.16
Adjusted Book Value	109.49	113.67	130.77	148.24	183.16

Cash Flow

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
	105.47	38.27	130.98	146.98	153.36
Adjustment	26.89	33.61	41.12	61.90	85.41
Changes In working Capital	-84.89	14.03	49.67	-126.79	-2.47
Cash Flow after changes in Working Capital	47.47	85.90	221.77	82.08	236.30
Cash Flow from Operating Activities	17.71	69.24	187.50	47.26	174.59
Cash Flow from Investing Activities	-31.64	-219.99	-206.41	-306.52	-226.93
Cash Flow from Financing Activitie	15.14	146.14	21.85	278.16	35.99
Net Cash Inflow / Outflow	1.21	-4.61	2.94	18.90	-16.35
Opening Cash & Cash Equivalents	7.96	9.16	4.55	7.50	26.39
Closing Cash & Cash Equivalent	9.16	4.55	7.50	26.39	10.04

Ratios

Valuation

74.30

5.45

35.34

9.40

17.10

233.38

Profitability

11.22

12.41

6.54

27.16

12.51

Leverage & Liquidity

0.34

0.92

6.87

Returns

0.00

0.52

Shareholding Pattern

Numbers in percentages

Particulars	Mar '24	Aug '26	Sep '26
	25.08	33.28	33.28
		47.47	36.56
	74.92	19.25	30.16
	74.92	66.72	66.72
No. of Shareholders	13	4,27,730	81,747

Mutual Funds Invested(37)

Based on each fund's latest monthly portfolio · Sep 2026

A total of 37 active funds hold 12.49% in Symbiotec Pharmalab Ltd., contributing to ₹945 Cr of holdings

Fund				As of
MO Motilal Oswal Small Cap Fund - Growth - Direct PlanSmall cap Fund	109.33	1.32	9,29,089	Sep '26
IP ICICI Prudential Small Cap Fund - Growth - Direct PlanSmall cap Fund	95.00	0.97	8,07,290	Sep '26
MI Mirae Asset Aggressive Hybrid Fund - Growth - Direct PlanHybrid - Aggressive Hybrid Fund	91.02	0.99	7,73,462	Sep '26
MI Mirae Asset Midcap Fund - Growth - Direct PlanMid Cap Fund	87.17	0.45	7,40,752	Sep '26
MI Mirae Asset Multicap Fund - Growth - Direct PlanMulti Cap Fund	64.72	1.20	5,50,000	Sep '26
MI Mirae Asset ELSS Tax Saver Fund - Growth - Direct PlanEquity - ELSS - Tax Saver Fund	64.44	0.26	5,47,602	Sep '26
MI Mirae Asset Small Cap Fund - Growth - Direct PlanSmall cap Fund	58.23	1.00	4,94,818	Sep '26
MI Mirae Asset Healthcare Fund - Growth - Direct PlanPharma & Health Care	55.81	1.60	4,74,270	Sep '26
HD HDFC Pharma and Healthcare Fund - Growth - Direct PlanPharma & Health Care	47.64	1.36	4,04,865	Sep '26
MM Mahindra Manulife Small Cap Fund - Growth - Direct PlanSmall cap Fund	29.78	0.55	2,53,050	Sep '26

Corporate Actions

Showing: All

Date	Type	Details	Ex-Date	Record Date
2026-10-28	Board Meeting	Quarterly Results
2026-09-11	Board Meeting	Quarterly Results

Insider Trading

Date	Person	Category	Transaction Type	Shares
2026-10-05	DEEPAK PATEL	Market	Sell	2,000
2026-10-05	DEVENDRA SINGH KUSHWAH	Market	Sell	1,000
2026-10-05	DHARM SHANKER PANDEY	Market	Sell	12,470
2026-10-05	JITENDRA SHARMA	Market	Sell	9,200
2026-10-05	MITESH PATEL	Market	Sell	11,500
2026-10-05	NISHIKANT Digambar GHADGE	Market	Sell	1,000
2026-10-05	PRATIMA KHATRI	Market	Sell	5,500
2026-10-05	RAJESH BHIMRAO MESHRAM	Market	Sell	7,000
2026-10-05	RAMAN PRASAD VERMA	Market	Sell	17,000
2026-10-05	SACHIN MADHUKAR CHAUDHARI	Market	Sell	2,500
2026-10-05	SUMAN PODDER	Market	Sell	15,000
2026-10-05	SUNIL KUMAR PANDEY	Market	Sell	8,500
2026-10-05	VIJAY SHARMA	Market	Sell	900
2026-10-05	VIJAY SHARMA	Market	Sell	2,000
2026-10-05	VIVEK ASTHANA	Market	Sell	1,000
2026-10-05	VIVEK ASTHANA	Market	Sell	5,500

Sector Overview

HealthcarePharmaceuticals & Drugs

Symbiotec Pharmalab Ltd. operates in the Healthcare sector under the Pharmaceuticals & Drugs industry. This sector is one of the key drivers of the Indian economy and is closely tracked by the relevant Nifty sectoral index.

Company Profile

Corporate information and contact details

Key Management

9 members across the board and senior leadership

Anil Satwani

Chairman & Managing Director

₹8.09 Cr

Mar '26

Rohit Mantri

Nominee Director

—

Hariharnath Buggana

Nominee Director

—

Dhananjay Mungale

Nominee Director

—

Sunita Kishnani

Non Executive Independent Director

₹2.00 L

Mar '26

Pratik Patel

Non Executive Independent Director

₹1.50 L

Mar '26

Pramod Kasat

Non Executive Independent Director

—

Richard Patrick Findlay Kenny

Non Executive Independent Director

—

Salil Jain

Company Secretary & Compliance Officer

—

SYMBIOTEC Latest News

News

6 of 6 articles

EQUITY1 Oct 2026 · 12:20

Symbiotec Pharmalab soars as its arm inks pact with leading global pharmaceutical company

The agreement marks a decisive step in the commercialization of Knovea’s DCV platform

COMPANY1 Oct 2026 · 11:52

Symbiotec Pharmalab’s arm inks pact with leading global pharmaceutical company

The agreement marks a decisive step in the commercialization of Knovea’s DCV platform

EQUITY29 Sept 2026 · 14:05

Symbiotec Pharmalab trades higher on the BSE

The company has received EIR from USFDA for Pithampur facility with VAI status

COMPANY29 Sept 2026 · 12:28

Symbiotec Pharmalab receives EIR from USFDA for Pithampur facility with VAI status

The inspection was conducted at the company’s manufacturing facility at Pithampur, from August 10, 2026 to August 14, 2026

EQUITY1 Sept 2026 · 10:24

Symbiotec Pharmalab make flat debut on the BSE

The scrip is currently trading at Rs. 982.05, down by 5.95 points or 0.60% from its issue price

IPO20 Aug 2026 · 17:33

Symbiotec Pharmalab coming with IPO to raise upto Rs 1,851 crore

The issue will open for subscription on August 24, 2026 and will close on August 27, 2026

Symbiotec Pharmalab Ltd.

Stock Overview

Price chart

Peer Comparison

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flow

Ratios

Valuation

Profitability

Leverage & Liquidity

Returns

Shareholding Pattern

Mutual Funds Invested(37)

Corporate Actions

Insider Trading

Sector Overview

Company Profile

Key Management

SYMBIOTEC Latest News

News